脂联素（adiponectin,ADPN）是一种抗炎脂肪因子,且其具有改善胰岛素抵抗及抗动脉粥样硬化等作用。分泌型卷曲相关蛋白-5（Secreted frizzled-related protein 5,SFRP5）被证实是继脂联素之后的又一抗炎脂肪因子,其可能通过炎症反应参...脂联素（adiponectin,ADPN）是一种抗炎脂肪因子,且其具有改善胰岛素抵抗及抗动脉粥样硬化等作用。分泌型卷曲相关蛋白-5（Secreted frizzled-related protein 5,SFRP5）被证实是继脂联素之后的又一抗炎脂肪因子,其可能通过炎症反应参与肥胖及糖尿病等代谢性疾病的发生[1]。目前,关于SFRP5与糖尿病微血管病变的研究少见报道。本研究通过测定糖尿病患者血清SFRP5、ADPN水平变化,探讨2型糖尿病患者血清SFRP5和ADPN水平与UAER的相关性及血清SFRP5和ADPN水平是否可以作为糖尿病肾病早期预测指标。展开更多
Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin res...Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5and sleeping characteristics as well as biochemical parameters of OSA patients.Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea–hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m2. All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive Creactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison.Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDLcholesterol level (r=?0.472 and P=0.003; r=?0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment.Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However,no correlation was observed between SFRP5 an展开更多
目的:研究SFRPs家族中SFRP1、SFRP2、SFRP4、SFRP5基因启动子区甲基化状况,探讨基因的甲基化与肾透明细胞癌发生发展的关系。方法:采用甲基化特异性PCR(methylation specific PCR,MSP)方法检测66例肾透明细胞癌及30例癌旁组织中SFRP1、S...目的:研究SFRPs家族中SFRP1、SFRP2、SFRP4、SFRP5基因启动子区甲基化状况,探讨基因的甲基化与肾透明细胞癌发生发展的关系。方法:采用甲基化特异性PCR(methylation specific PCR,MSP)方法检测66例肾透明细胞癌及30例癌旁组织中SFRP1、SFRP2、SFRP4、SFRP5基因启动子区甲基化状态及其与临床病理学资料之间的关系。结果:肾透明细胞癌组织中SFRP1、SFRP2、SFRP4、SFRP5基因甲基化率分别为77.3%(51/66)、72.7%(48/66)、59.1%(39/66)、69.7%(46/66),均显著高于相应的癌旁组织,结果有统计学意义(P<0.05)。与临床病理学资料相联系,肾透明细胞癌组织中SFRP1、SFRP5基因甲基化与肿瘤TNM分期相关;SFRP4基因甲基化与肿瘤的病理学分级相关(P<0.05)。结论:SFRP1、SFRP2、SFRP4、SFRP5基因的甲基化均可能参与肾透明细胞癌的发生。SFRP1、SFRP5基因甲基化可能与肾透明细胞癌的发展,浸润和转移有关。SFRP4基因甲基化可能与肾透明细胞癌的恶性行为有关。展开更多
目的探讨妊娠期糖尿病(GDM)孕妇孕期分泌型卷曲相关蛋白5(SFRP5)的表达与胰岛素抵抗的关系。方法筛选2016年1月~2017年3月在内蒙古自治区妇幼保健院产检的50名正常孕妇作为对照组,50例确诊为GDM的孕妇为实验组。比较两组孕24~28周空腹...目的探讨妊娠期糖尿病(GDM)孕妇孕期分泌型卷曲相关蛋白5(SFRP5)的表达与胰岛素抵抗的关系。方法筛选2016年1月~2017年3月在内蒙古自治区妇幼保健院产检的50名正常孕妇作为对照组,50例确诊为GDM的孕妇为实验组。比较两组孕24~28周空腹胰岛素、空腹血糖、血脂检查结果 ;采用酶联免疫吸附法对两组产妇剖宫产分娩时的肘静脉血清中的SFRP5表达水平进行检测;(3)分别取对照组及实验组各30例孕妇皮下脂肪,采取RT-PCR方法检测人脂肪细胞中SFRP5 m RNA的表达水平。结果两组孕妇血清与脂肪中均有SFRP5表达,实验组的血清及脂肪中的SFRP5表达水平显著低于对照组(P<0.01);血清SFRP5的表达与HOMA-IR、胆固醇、三酰甘油、低密度脂蛋白胆固醇呈负相关(r=-0.5706、-0.1479、-0.1541、-0.1366,均P<0.05),与高密度脂蛋白胆固醇呈正相关(r=0.0866,P<0.01)。结论 SFRP5的异常表达与GDM的发生发展有关,通过临床监测SFRP5的表达情况能早期发现胰岛素抵抗的发生,降低GDM发病率。因此,孕期对孕妇进行良好的营养指导,严格体重管理,可以减少胰岛素抵抗,改善GDM结局。展开更多
文摘脂联素（adiponectin,ADPN）是一种抗炎脂肪因子,且其具有改善胰岛素抵抗及抗动脉粥样硬化等作用。分泌型卷曲相关蛋白-5（Secreted frizzled-related protein 5,SFRP5）被证实是继脂联素之后的又一抗炎脂肪因子,其可能通过炎症反应参与肥胖及糖尿病等代谢性疾病的发生[1]。目前,关于SFRP5与糖尿病微血管病变的研究少见报道。本研究通过测定糖尿病患者血清SFRP5、ADPN水平变化,探讨2型糖尿病患者血清SFRP5和ADPN水平与UAER的相关性及血清SFRP5和ADPN水平是否可以作为糖尿病肾病早期预测指标。
文摘Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5and sleeping characteristics as well as biochemical parameters of OSA patients.Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea–hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m2. All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive Creactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison.Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDLcholesterol level (r=?0.472 and P=0.003; r=?0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment.Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However,no correlation was observed between SFRP5 an
文摘目的:研究SFRPs家族中SFRP1、SFRP2、SFRP4、SFRP5基因启动子区甲基化状况,探讨基因的甲基化与肾透明细胞癌发生发展的关系。方法:采用甲基化特异性PCR(methylation specific PCR,MSP)方法检测66例肾透明细胞癌及30例癌旁组织中SFRP1、SFRP2、SFRP4、SFRP5基因启动子区甲基化状态及其与临床病理学资料之间的关系。结果:肾透明细胞癌组织中SFRP1、SFRP2、SFRP4、SFRP5基因甲基化率分别为77.3%(51/66)、72.7%(48/66)、59.1%(39/66)、69.7%(46/66),均显著高于相应的癌旁组织,结果有统计学意义(P<0.05)。与临床病理学资料相联系,肾透明细胞癌组织中SFRP1、SFRP5基因甲基化与肿瘤TNM分期相关;SFRP4基因甲基化与肿瘤的病理学分级相关(P<0.05)。结论:SFRP1、SFRP2、SFRP4、SFRP5基因的甲基化均可能参与肾透明细胞癌的发生。SFRP1、SFRP5基因甲基化可能与肾透明细胞癌的发展,浸润和转移有关。SFRP4基因甲基化可能与肾透明细胞癌的恶性行为有关。
文摘目的探讨妊娠期糖尿病(GDM)孕妇孕期分泌型卷曲相关蛋白5(SFRP5)的表达与胰岛素抵抗的关系。方法筛选2016年1月~2017年3月在内蒙古自治区妇幼保健院产检的50名正常孕妇作为对照组,50例确诊为GDM的孕妇为实验组。比较两组孕24~28周空腹胰岛素、空腹血糖、血脂检查结果 ;采用酶联免疫吸附法对两组产妇剖宫产分娩时的肘静脉血清中的SFRP5表达水平进行检测;(3)分别取对照组及实验组各30例孕妇皮下脂肪,采取RT-PCR方法检测人脂肪细胞中SFRP5 m RNA的表达水平。结果两组孕妇血清与脂肪中均有SFRP5表达,实验组的血清及脂肪中的SFRP5表达水平显著低于对照组(P<0.01);血清SFRP5的表达与HOMA-IR、胆固醇、三酰甘油、低密度脂蛋白胆固醇呈负相关(r=-0.5706、-0.1479、-0.1541、-0.1366,均P<0.05),与高密度脂蛋白胆固醇呈正相关(r=0.0866,P<0.01)。结论 SFRP5的异常表达与GDM的发生发展有关,通过临床监测SFRP5的表达情况能早期发现胰岛素抵抗的发生,降低GDM发病率。因此,孕期对孕妇进行良好的营养指导,严格体重管理,可以减少胰岛素抵抗,改善GDM结局。
